The new strategies in diabetes mellitus treatment The rational selection of oral antidiabetics in diabetes mellitus treatment, type II is determined by the influence upon pathogenic way, prevention of insulinoresistance and insulin secretion insufficiency. With this purpose can be utilized sulphonylureic (glybenclamide, glypiyide, glymepiride etc.), biguanides (metphormine), meglytinedes (repaglynide, nateglynide), thyayolidindiones (pioglytazon, roziglytazon), tetrazaharides (acarboze), GLP-1 agonists (exenatid, liraglutid), DPP/IV antagonists and blockers (sitaglipide, vildaglyptide, saxaglyptine), antagonists of GB1 canabinoid reseptors (rimonobant), amilines analogues (pramliptid), ihaled insulin (exiubera).

Selectarea raţională a antidiabeticelor orale în tratamentul diabetului zaharat tip 2 este determinată de influenţa asupra verigelor patogenetice, combaterea insulinorezistenţei şi insuficienţei secreţiei insulinei. Cu acest svop se pot utiliza: sulfonilureicele (glibenclamida, glipizida, glimepirida etc.), biguanidele (metformina), meglitinidele (repaglinida, nateglinida), tiazolidindionele (pioglitazon, roziglitazon), tetrazaharidele (acarboza), agoniştii GLP-1 (exenatid, liraglutid), antagoniştii sau blocantele DPP-IV (sitagliptina, vildagliptina, saxagliptina), antagoniştii GB1-receptorilor canabinoizi (rimonobant), analogii amilinei (pramliptid), insulina inhalatoare (exiubera).